| Literature DB >> 32599940 |
Huijuan Li1, Shibin Liu1, Yongqian Du1, Jie Tan1, Jiezhang Luo1, Yulong Sun2.
Abstract
At present, studies on macrophage proteins mainly focus on biological stimuli, with less attention paid to the responses of macrophage proteins to physical stimuli, such as electric fields. Here, we exploited the electric field-sensitive hub proteins of macrophages. RAW 264.7 macrophages were treated with a direct current electric field (dcEF) (200 mV/mm) for four hours, followed by RNA-Seq analysis. Differentially expressed genes (DEGs) were obtained, followed by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) and protein-protein interaction (PPI) analysis. Eight qPCR-verified DEGs were selected. Subsequently, three-dimensional protein models of DEGs were modeled by Modeller and Rosetta, followed by molecular dynamics simulation for 200 ns with GROMACS. Finally, dcEFs (10, 50, and 500 mV/mm) were used to simulate the molecular dynamics of DEG proteins for 200 ns, followed by trajectory analysis. The dcEF has no obvious effect on RAW 264.7 morphology. A total of 689 DEGs were obtained, and enrichment analysis showed that the steroid biosynthesis pathway was most affected by the dcEF. Moreover, the three-dimensional protein structures of hub proteins were constructed, and trajectory analysis suggested that the dcEF caused an increase in the atomic motion of the protein in a dcEF-intensity-dependent manner. Overall, we provide new clues and a basis for investigating the hub proteins of macrophages in response to electric field stimulation.Entities:
Keywords: RNAs-seq; bioinformatics analysis; direct current electric field (dcEF); macrophage; molecular dynamics simulation
Year: 2020 PMID: 32599940 PMCID: PMC7352442 DOI: 10.3390/ijms21124505
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Basic information on RAW 264.7 cells and RNA-Seq. (a) The cell morphology of RAW 264.7 cells during the direct current electric field (dcEF) 200 mV/mm treatment. Scale bar, 100 μm. (b) The boxplot of gene expression distribution. (c) Violin plot. (d) The proportion of the sequenced genes. (e) Volcano plot showing metabolomic data (up-regulated genes were represented as red dots and down-regulated genes were indicated as green dots). (f) Venn diagram showed the number of overlap genes during the different groups. (g) Heat map of the differentially expressed genes.
Details of Long non-coding RNA (lncRNA) and MicroRNA (miRNA).
| Gene_Biotype | Gene_Name | log2FoldChange | Padj | |
|---|---|---|---|---|
| lncRNA |
| −2.470287104 | 1.61 × 10−13 | 4.04 × 10−10 |
|
| −2.088392064 | 9.78 × 10−12 | 1.85 × 10−8 | |
|
| −3.034810761 | 1.58 × 10−9 | 1.71 × 10−6 | |
|
| −3.026474908 | 5.02 × 10−9 | 4.46 × 10−6 | |
|
| −1.323550221 | 1.30 × 10−8 | 7.69 × 10−6 | |
|
| −2.836327803 | 1.36 × 10−7 | 4.89 × 10−5 | |
|
| −1.74087554 | 1.06 × 10−6 | 0.000208401 | |
|
| 2.480747891 | 4.30 × 10−6 | 0.000612157 | |
|
| 1.061737181 | 1.69 × 10−5 | 0.001775738 | |
|
| −2.393353924 | 2.72 × 10−5 | 0.002486353 | |
|
| −1.934651075 | 3.57 × 10−5 | 0.003014666 | |
|
| −2.461324991 | 5.86 × 10−5 | 0.004243817 | |
|
| −1.680214964 | 7.70 × 10−5 | 0.005032238 | |
|
| −2.201929478 | 0.000168331 | 0.008675651 | |
|
| −1.230352255 | 0.000211049 | 0.010247751 | |
|
| −2.439159554 | 0.000218217 | 0.010395258 | |
|
| −1.345909825 | 0.000265851 | 0.011965918 | |
|
| −1.806478371 | 0.00035872 | 0.014640637 | |
|
| −2.092545053 | 0.000750651 | 0.023785141 | |
|
| 1.207513949 | 0.001022396 | 0.029021064 | |
|
| 1.203380022 | 0.001192886 | 0.031492603 | |
|
| 1.042574015 | 0.001198205 | 0.031522819 | |
|
| −2.920635148 | 0.001270895 | 0.032583666 | |
|
| −2.486096408 | 0.001308696 | 0.033258798 | |
|
| −2.19928712 | 0.001578787 | 0.036963198 | |
|
| −1.366279119 | 0.001838241 | 0.040183135 | |
|
| −2.327597738 | 0.001839189 | 0.040183135 | |
|
| −1.260055171 | 0.001948831 | 0.041708195 | |
|
| −1.315142974 | 0.002101718 | 0.043726474 | |
|
| −2.842246271 | 0.002255472 | 0.046214222 | |
| miRNA |
| 9.74 × 10−7 | 0.000196164 | Gm23935 |
|
| 2.73 × 10−6 | 0.000453662 | Gm24270 | |
|
| 3.27 × 10−6 | 0.000523127 | miR 142b | |
|
| 4.69 × 10−5 | 0.003747572 | miR 23a | |
|
| 5.96 × 10−5 | 0.004258302 | miR 365-2 | |
|
| 0.000355791 | 0.014599983 | miR 23b | |
|
| 0.000605588 | 0.021022951 | miR 27a | |
|
| 0.000608768 | 0.021077429 | miR 221 | |
|
| 0.000680236 | 0.022379617 | miR 7-1 |
Figure 2Functional and pathway enrichment analysis of identified modules associated with differentially expressed genes (DEGs). The DEGs were subjected to Gene Ontology (GO) classification using the PANTHER (Protein ANalysis THrough Evolutionary Relationships) GO classification system. (a) Bar graph of enriched terms of the genes (colored by p-values). (b) Biological process (BP). (c) Cellular component (CC). (d) Molecular function (MF). (e) Network maps of GO terms (GO dot). The abscissa is the ratio of the number of differentially expressed genes, which annotates the GO term to the total number of differentially expressed genes.
Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) pathway analysis of up-regulated and down-regulated DEGs.
| Expression | Pathway ID | Name | Gene Count | % | Genes |
|---|---|---|---|---|---|
| Down-regulated | mmu01100 | Metabolic pathways | 32 | 15.69 |
|
| mmu05200 | Pathways in cancer | 7 | 3.43 |
| |
| mmu04152 | AMP-activated protein kinase (AMPK) signaling pathway | 6 | 2.94 |
| |
| mmu00100 | Steroid biosynthesis | 6 | 2.94 |
| |
| mmu00900 | Terpenoid backbone biosynthesis | 6 | 2.94 |
| |
| Up-regulated | mmu01100 | Metabolic pathways | 49 | 24.02 |
|
| mmu05200 | Pathways in cancer | 17 | 8.33 |
| |
| mmu04151 | PI3K-Akt (Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)) signaling pathway | 12 | 5.88 |
| |
| mmu05202 | Transcriptional misregulation in cancer | 10 | 4.9 |
| |
| mmu05170 | Human immunodeficiency virus 1 infection | 9 | 4.41 |
|
Figure 3The 10 hub genes were mapped for functional enrichment analysis using the ClueGo tool. (a) The enriched pathways of 10 genes (different pathways were represented by different colors). (b) Pathway enrichment analysis with ClueGO for the 10 hub genes.
Figure 4RNA-Seq results were verified by qPCR for DEGs of RAW 264.7 cells in response to the dcEF. RAW 264.7 cells were treated with a dcEF of 200 mV/mm for four hours, followed by gene expression examination. The total RNA was isolated, and a qPCR test was carried out. The mRNA expression was normalized to the expression of GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase). * significantly different from control; * p < 0.05; ** p < 0.01; and *** p < 0.001. n = 3 for each test in duplicate. The final data are shown as means ± SEM, and the statistical significance of results was analyzed by a t-test.
Figure 5The structure of the three-dimensional protein of DEGs optimized by molecular dynamics. For each protein, from left to right, respectively: three-dimensional protein modeling structure, three-dimensional protein structure of the lowest energy for DEGs after molecular dynamics simulation of 0, 0.01, 0.05, and 0.5 v direct current electric field. Here, the three-dimensional protein structures of Eid3 (a), Lrp8 (b), Ldlr (c), Insig1 (d), Fcgr1 (e), Ypel3 (f), Hcar2 (g), and Mmp9 (h) are shown. The picture was drawn by the Pymol software (Delano, W.L. The Pymol Molecular Graphics System (2002) DeLano Scientific, SanCarlos, CA, USA. http://www.pymol.org).
Protein modeling.
| Proteins | Species | Protein Length (aa) | Model Templates (Query Cover, Identify) |
|---|---|---|---|
| LRP8 | Mus musculus | 498 | 5B4X_B (66%, 93.05%) |
| LDLR | Mus musculus | 862 | 1IJQ_A (36%, 85.80%) |
| FCGR1 | Mus musculus | 404 | 4ZNE_A (65%, 73.31%) |
| HCAR2 | Mus musculus | 360 | 5XJM_A (31%, 38.94%) |
| MMP9 | Mus musculus | 730 | 1L6J_A (58%, 82.16%) |
| EID3 | Mus musculus | 375 | de novo |
| INSIG1 | Mus musculus | 259 | de novo |
| YPEL3 | Mus musculus | 119 | de novo |
Figure 6Ramachandran plot of the selected homology modeled 3D protein structures of DEGs. The different colored areas show ‘disallowed’ (beige), ‘generously allowed’ (yellow) and ‘most favored’ (red) regions.
Ramachandran plot analysis.
| Proteins | Number of Residues in Favored Region | Number of Residues in Allowed Region | Number of Residues in Disallowed Region |
|---|---|---|---|
| LRP8 | 354 (80.3%) | 82 (18.6%) | 5 (1.1%) |
| LDLR | 466 (81.3%) | 97 (16.9%) | 10 (1.7%) |
| FCGR1 | 302 (86.5%) | 42 (12.0%) | 5 (1.4%) |
| HCAR2 | 271 (83.4%) | 50 (15.3%) | 4 (1.2%) |
| MMP9 | 531 (89.5%) | 59 (10.0%) | 3 (0.5%) |
| EID3 | 322 (93.6%) | 22 (6.4%) | 0 (0.0%) |
| INSIG1 | 201 (93.5%) | 14 (6.5%) | 0 (0.0%) |
| YPEL3 | 96 (89.7%) | 11 (10.3%) | 0 (0.0%) |
For Ldlr and Mmp9, part of the N-terminus was removed for subsequent molecular dynamics simulation.
Figure 7Root mean square deviation (RMSD) comparison plots of backbone Cα atoms during molecular dynamics simulation (at least >200 ns). In order to clearly illustrate the deviations of the DEG proteins, the RMSD plots are shown. The RMSD of Eid3, Lrp8, Ldlr, Insig1, Fcgr1, Ypel3, Hcar2, and Mmp9 are shown. For each protein, 0 mV (black), (red), 50 mV (green), and 500 mV (blue) are displayed on the map.
dcEF-sensitive genes.
| Name Ensembl ID | Species Gene Type | Location Length | Expression Changes (dcEF vs. Control) | Protein Families | Function | Refs |
|---|---|---|---|---|---|---|
| Mus musculus Protein coding | Chr3 (2589 bp) | Up-regulated | PTHR11481 (14 genes) | Anticipated in the signal transduction of pain such as arthritis and joint inflammation. | [ | |
| Mus musculus Protein coding | Chr7 (1057 bp) | Up-regulated | PTHR13847_SF179 (1 gene) | A novel tumor suppressor. | [ | |
| Mus musculus Protein coding | Chr5 (1930 bp) | Up-regulated | PTHR24231 (14 genes) | A novel negative regulator of macrophage activation. | [ | |
| Mus musculus Protein coding | Chr2 (3175 bp) | Up-regulated | PTHR10201_SF30 (1 gene) | Involved in a wide range of biological functions including macrophage differentiation, inflammation, bone metabolism, and tumor invasion. | [ | |
| Mus musculus Protein coding | Chr10 (1305 bp) | Down-regulated | PTHR16140_SF1 (1 gene) | A potent suppressor of nuclear receptor transcriptional activity. | [ | |
| Mus musculus Protein coding | Chr3 (3291 bp) | Down-regulated | PTHR10529_SF99 (1 gene) | A modulator of cell development and migration. | [ | |
| Mus musculus Protein coding | Chr9 (4549 bp) | Down-regulated | PTHR10529_SF195 (1 gene) | Deeply regulates the metabolism of lipids. | [ | |
| Mus musculus Protein coding | Chr5 (2667 bp) | Down-regulated | PTHR15301 (2 genes) | Modulates innate immunity and cholesterol metabolism. | [ |
GO analysis of dcEF-sensitive genes.
| Genes | GO Analysis [ |
|---|---|
|
| MF: signaling receptor activity; signaling receptor binding. |
| BP: cellular component organization; establishment of localization; immune system process; protein metabolic process; response to stimulus; signaling. | |
| CC: plasma membrane. | |
|
| MF: none. |
| BP: cell death; response to stimulus. | |
| CC: nucleus. | |
|
| MF: carbohydrate derivative binding; signaling receptor activity. |
| BP: cell death; establishment of localization; homeostatic process; immune system process; lipid metabolic process; response to stimulus; signaling. | |
| CC: plasma membrane. | |
|
| MF: hydrolase. |
| BP: cell death; cell differentiation; cell population proliferation; cellular component organization; establishment of localization; immune system process; protein metabolic process; response to stimulus; signaling; system development. | |
| CC: extracellular region. | |
|
| MF: none. |
| BP: response to stimulus. | |
| CC: non-membrane-bounded organelle; nucleus; organelle lumen. | |
|
| MF: cytoskeletal protein binding; signaling receptor activity. |
| BP: cell death; cell differentiation; cellular component organization; establishment of localization; immune system process; nucleic acid-templated transcription; protein metabolic process; response to stimulus; signaling; system development. | |
| CC: cell projection; cytoskeleton; extracellular region; non-membrane-bounded organelle; plasma membrane; synapse. | |
|
| MF: none. |
| BP: cell differentiation; cellular component organization; establishment of localization; homeostatic process; immune system process; lipid metabolic process; protein metabolic process; response to stimulus; system development. | |
| CC: cytoplasmic vesicle; endosome; extracellular region; Golgi apparatus; plasma membrane; vacuole. | |
|
| MF: none. |
| BP: cell differentiation; cellular component organization; establishment of localization; homeostatic process; lipid metabolic process; nucleic acid-templated transcription; response to stimulus; signaling; system development. | |
| CC: endoplasmic reticulum. |
This information was from the Mouse Genome Database (MGD) at the Mouse Genome Informatics website, the Jackson Laboratory, Bar Harbor, Maine (URL: http://www.informatics.jax.org) [37,38] [date of retrieving data: August 12, 2019].
dcEF-sensitive lncRNAs.
| Name Ensembl ID | Species Gene Type | Location Length | Changes (dcEF vs. Control) | Function | Refs |
|---|---|---|---|---|---|
| Mus musculus LncRNA | Chr12 (1697 bp) | Down-regulated | May be related to the maturation of red blood cells. No specific function reported yet. | [ | |
| Mus musculus LncRNA | Chr12 (1423 bp) | Down-regulated | No specific function reported yet. | [ | |
| Mus musculus LncRNA | Chr8 (690 bp) | Down-regulated | No specific function reported yet. | [ | |
| Mus musculus LncRNA | Chr1 (2134 bp) | Down-regulated | May be related to mammary tumor cell proliferation and migration. | [ | |
| Mus musculus LncRNA | Chr11 (627 bp) | Down-regulated | Promote tumor cell proliferation. | [ |
Comparison of EF-induced gene expression pathway changes in human and mouse samples.
| Pathway Name | Fold Change or | |||||
|---|---|---|---|---|---|---|
| HDF-a dcEF: 100 mV/mm 1 h [ | Human Adult Epidermal Keratinocytes dcEF: 100 mV/mm 1 h [ | CL1–5 dcEF: 300 mV/mm 2 h [ | U87 mg dcEF: 250 mV/mm 8 h [ | DAOY dcEF: 250 mV/mm 8 h [ | RAW 264.7 dcEF: 200 mV/mm 4 h | |
| Transcription | YAF2: 2.6 | WNK1: 1.8 | NFYA: 1.16 | Gene: NA | Gene: NA | Gadd45a: 3.25 |
HDF-a: the human adult dermal fibroblast cell line; CL1–5: the human lung cancer cell line; U87 mg: the human glioblastoma cell line; DAOY: the human medulloblastoma cell line; RAW 264.7: the murine macrophage cell line; and NA: not available. Gene name list: NFYA: nuclear transcription factor Y, alpha; NFYC: nuclear transcription factor Y, gamma; YAF2: YY1 associated factor 2; JMJD1C: Jumonji domain containing 1C; ZBTB24: zinc finger and BTB domain (Broad-Complex, Tramtrack and Bric a brac) containing 24; ZNF15L1: zinc finger protein 708 (KOX8); LRRFIP1: leucine rich repeat (in FLII) interacting protein 1; ZNF207: zinc finger protein 207; RNF12: ring finger protein 12; SIX1: sine oculis homeobox homolog 1 (Drosophila); FOXJ1: Forkhead box J1; ITPR1: inositol 1,4,5-triphosphate receptor, type 1; IL1RAPL1: interleukin 1 receptor accessory protein-like 1; MAPK1: mitogen-activated protein kinase 1; WNK1: WNK lysine deficient protein kinase 1; RAB6IP2: RAB6 interacting protein 2; PICALM: phosphatidylinositol binding clathrin assembly protein; ATP11B: ATPase, Class VI, type 11B; CENTG2: centaurin, gamma 2; SEC15L2: SEC15-like 2 (S. cerevisiae); AP3B1: adaptor-related protein complex 3, beta 1 subunit; ATP6V0E: ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e; FLVCR: feline leukemia virus subgroup C cellular receptor; Gadd45a: growth arrest and DNA-damage-inducible 45 alpha; Ddit3: DNA-damage inducible transcript 3; Fcgr1: Fc receptor, IgG, high affinity I; Lmo2: LIM domain only 2; Mmp9: matrix metallopeptidase 9; Traf1: TNF receptor-associated factor 1; Nupr1: nuclear protein transcription regulator 1; Mllt3: myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3; Nfkbiz: nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta; Hist2h3c2: histone cluster 2, H3c2.
Figure 8Schematic diagram. (a) Study workflow. Red object: cell; blue arrow: direction of electric field. (b) The schematic diagram of the movement of cells in the electric field. (c) The structure of the chamber. (d) The electric field chamber in the incubator.
Primers used for qPCR.
| Primers | Sequences (5′ to 3′) | Product (bp) | |
|---|---|---|---|
|
| Forward | TGTGTCCGTCGTGGATCTGA | 150 |
| Reverse | TTGCTGTTGAAGTCGCAGGAG | ||
|
| Forward | GGTTCCTCAATGCCAAGT | 128 |
| Reverse | TTATTCTTCCATCCGTGACA | ||
|
| Forward | ACCTCTTCAACTCTGTAGTG | 154 |
| Reverse | TACTTCTGGCTGCTCTCA | ||
|
| Forward | ACTGTCCACCTCCTCTATAC | 194 |
| Reverse | TGTCTGTCCATCTGTCTCT | ||
|
| Forward | AGATTCTCCGTGTCCTGTA | 163 |
| Reverse | AGTCTGACCTGAACCATAAC | ||
|
| Forward | TAGCGACTGCGATGATAG | 187 |
| Reverse | CATATCTCCACTTCCTTCCA | ||
|
| Forward | GACAAGGAGTAAGAAGAATGAG | 115 |
| Reverse | ACAGCAGCGAGTGAATAC | ||
|
| Forward | GTGTGAAGATATTGACGAGTG | 162 |
| Reverse | TTGGTGAAGAGCAGATAGC | ||
|
| Forward | CTAAGAGTGAGTCGCTGTC | 196 |
| Reverse | GTGTTGTGTTCTATGCTGTC | ||
|
| Forward | GGTCTGTGCTTAGTCTCTG | 156 |
| Reverse | TGCTACCTGGAACCTTGT | ||
|
| Forward | CAATGGTGGAGGAGAGGA | 124 |
| Reverse | GATGCTAGTGAGGTCAAGAA | ||
|
| Forward | GCCTCAGGATATGAACAGAT | 131 |
| Reverse | TCAGCCAGTTCCAATTAGTC | ||
|
| Forward | CCAACACATATACAGCAGAAG | 124 |
| Reverse | TCCACCTCCTATCCTCCT | ||
|
| Forward | CTGGCTGCTTCTGTGTTG | 123 |
| Reverse | TGCTTCCGTCTAGTCGTT |